SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger…

Passage BIO, Inc. · 8-K filed Sep 2, 2026 at 21:37 ET

At the news

BULLISHIMPACT 8/10

8-K filed Sep 2, 2026 at 21:37 ET

Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, with a concurrent $99.9M PIPE financing. The combined company will operate under the Remix name and pipeline, with Passage's existing assets (Legacy Assets) being divested and their proceeds distributed to Passage's pre-merger shareholders via Contingent Value Rights (CVRs). This is a transformative event that effectively replaces Passage's business with Remix's, making it a new entity for investors.

  • Passage Bio is acquiring Remix Therapeutics via a two-step merger, with Remix valued at $226M in equity.
  • A concurrent PIPE financing of at least $99.9M is being raised to fund the combined company.
  • Passage's existing assets (Legacy Assets) will be sold, with proceeds distributed to pre-merger Passage shareholders through CVRs.
  • The combined company will be named Remix Therapeutics, Inc., and Passage's current management will be replaced by Remix's team.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access